Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
568 Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)
Compose a Response to This Article
Other responses
No responses have been published for this article.